本文關(guān)鍵詞：蛋白酪氨酸激酶信號轉(zhuǎn)導(dǎo)途徑與抗腫瘤藥物，由筆耕文化傳播整理發(fā)布。

來源： 關(guān)鍵字： ,蛋白酪氨酸激酶信號轉(zhuǎn)導(dǎo)途徑與抗腫瘤藥物

延伸：酪氨酸激酶受體的信號轉(zhuǎn)導(dǎo)途徑與腫瘤治療
本文除了提供蛋白酪氨酸激酶信號轉(zhuǎn)導(dǎo)途徑與抗腫瘤藥物 第12頁的文本下載，還提供與之相關(guān)的《酪氨酸激酶受體的信號轉(zhuǎn)導(dǎo)途徑與腫瘤治療》文本文檔，希望對您有所幫助。

·334·藥學(xué)學(xué)報ActaPharmaceuticaSinica2008,43(4):323-334

Inhibitionof

[34]ZhengHY,HuJD,ZhengZH,etal.Emodininduces

leukemicHL260cellsapoptosisprobablybyinhibitingAktsignalpathway[J].ActaPharmSin(藥學(xué)學(xué)報),2007,42:1142-1146.

[35]BoschelliDH,WuB,YeF,etal.SynthesisandSrc

Safety,

kinaseinhibitoryactivityofaseriesof42[(2,42dichloro252methoxyphenyl)amino]272furyl232quinolinecarbonitriles[J].JMedChem,2006,49:7868-7876.

[36]GorreME,MohammedM,EllwoodK,etal.Clinical

resistancetoSTI571cancertherapycausedbyBcr2Ablgenemutationoramplification[J].Science,2001,293:876-880.

[37]SchenoneS,ManettiF,BottaM.Lastfindingsondual

inhibitorsofAblandSrc[J].MiniRevMedm,7:.

[38]M.secondgenerationc2

inhibitors

managementofgastrointestinalmors[J].ClinColorectalCancer,2006,6:30-34.

[39]JabbourE,CortesJE,GilesFJ,etal.

[J].Cancer,2007,109:2171-2181.

[40]O’SullivanLA,LiongueC,LewisRS,etal.Cytokine

TargetingtheERKsignaling

receptorsignalingthroughtheJak2Stat2Socspathwayindisease[J].MolImmunol,2007,44:2497-2506.[41]KumarS,RajeN,HideshimaT,etal.Antimyeloma

activityoftwonovelN2substitutedandtetraflourinatedthalidomideanalogs[J].Leukemia,2005,19:1253-1261.[42]BartonBE,

KarrasJG,MurphyTF,

etal.

Signal

transducerandactivatoroftranscription3(STAT3)activationinprostatecancer:directSTAT3inhibitioninducesapoptosisinprostatecancerlines[J].MolCancerTher,2004,3:11-20.

[43]BlaskovichMA,SunJ,CantorA,etal.Discoveryof

JSI2124(CucurbitacinI),aselectiveJanuskinase/signaltransducerandactivatoroftranscription3signalingpathwayinhibitorwithpotentantitumoractivityagainsthumanandmurinecancercellsinmice[J].Cancer

Mechanismsof

Res,2003,63:1270-1279.

[44]SchenoneS,BondavalliF,BottaM.

Antiangiogenic

agents:anupdateonsmallmoleculeVEGFRinhibitors[J].CurrMedChem,2007,14:2495-2516.

[45]DudaDG,JainRK,WillettCG.Antiangiogenics:the

potentialroleofintegratingthisnoveltreatmentmodalitywithchemoradiationforsolidcancers[J].JClinOncol,2007,25:4033-4042.

Currentand

emergingtreatmentoptionsinchronicmyeloidleukemia

[21]InaiT,MancusoM,HashizumeH,etal.

vascularendothelialgrowthfactor(VEGF)signalingincancercauseslossofendothelialfenestrations,regressionoftumorvessels,andappearanceofbasementmembraneghosts[J].AmJPathol,2004,165:35-52.[22]RosenLS,

KurzrockR,MulayM,

etal.

pharmacokinetics,andefficacyofAMG706,anoralmultikinaseinhibitor,inpatientswithadvancedsolidtumors[J].JClinOncol,2007,25:2369-2376.[23]WongKK.HKI2272innon2smallcelllungcancer[J].

ClinCancerRes,2007,13:4593-4596.

[24]YounesMN,YaziciYD,KimS,etal.Dualepidermal

growthfactorreceptorandvascularendothelialgrowthfactorreceptorinhibitionwithNVP2AEE788forthetreatmentofaggressivefollicularthyroidcancer[J].ClinCancerRes,2006,12:3425-3434.[25]Harousseau

173-182.

[26]ReuterCW,nV,vasculargrowthfactor(VEGF)2receptor2signalingincellcarcinoma[J].WorldJUrol,2007,25:59-72.[27]KohnoM,PouyssegurJ.

200-211.

[28]MaFY,FlancRS,TeschGH,etal.Apathogenicrole

forc2Junamino2terminalkinasesignalinginrenalfibrosisandtubularcellapoptosis[J].2007,18:472-484.

[29]VivancoI,SawyersCL.Thephosphatidylinositol32kinase

AKTpathwayinhumancancer[J].NatRevCancer,2002,2:489-501.

[30]Drugsmovingintotheclinic[EB/OL].2007:1-39.

[31]delaPenaL,BurganWE,CarterDJ,etal.Inhibitionof

Aktbythealkylphospholipidperifosinedoesnotenhancetheradiosensitivityofhumangliomacells[J].MolCancerTher,2006,5:1504-1510.[32]MacKenzieAR,

vonMehrenM.

mammaliantargetofrapamycininhibitioninsarcoma:presentandfuture[J].2007,7:1145-1154.

[33]MartelliAM,TazzariPL,EvangelistiC,etal.Targeting

thephosphatidylinositol32kinase/Akt/mammaliantargetofrapamycinmoduleforacutemyelogenousleukemiatherapy:frombenchtobedside[J].CurrMedChem,2007,14:2009-2023.

ExpertRevAnticancerTher,

JAmSocNephrol,

pathwayincancertherapy[J].AnnMed,2006,38:

JL.

Farnesyltransferase

hematologicmalignancies[J].Blood

第12頁/共12頁

猜您感興趣

查看更多相關(guān)文本

編輯推薦

我也來解決

  本文關(guān)鍵詞：蛋白酪氨酸激酶信號轉(zhuǎn)導(dǎo)途徑與抗腫瘤藥物，，由筆耕文化傳播整理發(fā)布。